Adap­ti­m­mune surges af­ter FDA lifts par­tial hold; An­thera tanks on PhI­II flop; Kad­mon ax­es staffers in re­struc­tur­ing

Adap­ti­m­mune stock $ADAP surged 14% af­ter the com­pa­ny re­vealed in its Q3 up­date that the FDA had lift­ed its par­tial hold on its lead pro­gram. When it was first an­nounced in Au­gust, the UK biotech hur­ried to ex­plain that the FDA was look­ing for a few an­swers to ques­tions posed by reg­u­la­tors ahead of the launch of the reg­is­tra­tion tri­al.

Shares of An­thera $ANTH were bat­tered ear­ly Thurs­day morn­ing when the small biotech an­nounced that its Phase III lu­pus study of blis­i­bi­mod flopped, with 47% of the pa­tients hit­ting the pri­ma­ry end­point along­side 42% of the place­bo arm. Its shares cratered, plung­ing 39%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER